Jun 12 Cardiology NewsJun 12 Cardiology News
The FDA Advisory Committee ruling on PCSK9 drugs, sitagliptin and CV risk, PPI use and MI risk, and the role of stress in heart disease are reviewed by Dr Mandrola. theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 12, 2015 Category: Cardiology Tags: Cardiology News Source Type: news
AstraZeneca’s data analysis reveals no increased risk with saxagliptin for hHF patients
AstraZeneca has presented the results of an observational and retrospective study, which demonstrated that no evidence of increased risk of hospitalisation for heart failure (hHF) with saxagliptin compared against sitagliptin. (Source: Drug Development Technology)
Source: Drug Development Technology - June 11, 2015 Category: Pharmaceuticals Source Type: news
Merck Diabetes Drug Trial Meets Primary Endpoint
Treatment with Sitagliptin did not increase risk of cardiovascular events in primary composite endpoint, or hospitalization for heart failure, compared with placebo (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 9, 2015 Category: Pharmaceuticals Source Type: news
Sitagliptin Doesn't Appear to Raise Cardiovascular Risk (FREE)
By Kelly Young
Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD
The addition of sitagliptin to usual care in patients with type 2 diabetes and cardiovascular disease doesn't seem to increase the risk for cardiovascular events, according to an industry-funded study … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 9, 2015 Category: Primary Care Source Type: news
TECOS: No CVD Risks or Heart Failure With SitagliptinTECOS: No CVD Risks or Heart Failure With Sitagliptin
The TECOS study showed sitagliptin was not associated with any signal of cardiovascular risk and, importantly, absolutely no increase in the risk of heart failure, a signal that has been observed with other DPP-4 inhibitors. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 8, 2015 Category: Cardiology Tags: Cardiology News Source Type: news
Giant Study Boosts Januvia, Merck's $6 Billion Drug
Januvia, a widely used diabetes drug that generates $6 billion in annual sales for maker Merck, does not increase patients’ risk of being hospitalized for heart failure, a risk that did show up in clinical trials of competing drugs. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 8, 2015 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news
No heart safety issues seen with Merck Januvia diabetes drug: study
(Reuters) - Details of a large heart safety study presented on Monday appear to give Merck and Co's diabetes drug Januvia a clean bill of health, possibly setting the stage for a return to sales growth for the drugmaker's biggest product. (Source: Reuters: Health)
Source: Reuters: Health - June 8, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
ADA: Sitagliptin No Risk, No Benefit for Heart (CME/CE)
(MedPage Today) -- Long-awaited TECOS results show no difference in heart events between treatment and placebo (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 8, 2015 Category: Cardiology Source Type: news
TECOS, Merck’s Cardiovascular Safety Trial of JANUVIA (sitagliptin), Met Primary Endpoint in Patients with Type 2 Diabetes
Dateline City:
KENILWORTH, N.J.
Findings Published in the New England Journal of Medicine and Presented at the American Diabetes Association Scientific Sessions
Treatment with Sitagliptin Did Not Increase the Risk of Major Adverse Cardiovascular Events in the Primary Composite Endpoint, or Hospitalization for Heart Failure, Compared with Placebo
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today anno...
Source: Merck.com - Product News - June 8, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Diabetes Drug Trials Headline ADA 2015
(MedPage Today) -- Highly anticipated results from sitagliptin and lixisenatide trials to be announced (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 4, 2015 Category: Cardiology Source Type: news
India Supreme Court Rules in Favor of Merck in Diabetes Drug Patent Suit
The Supreme Court of India has barred Mumbai-based Glenmark Pharmaceuticals from making and selling generic versions of U.S. drugmaker Merck's diabetes drugs, Januvia and Janumet. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 19, 2015 Category: Pharmaceuticals Source Type: news
Indian court bars Glenmark from selling Merck drug copies
MUMBAI (Reuters) - India's Supreme Court has barred Glenmark Pharmaceuticals from making and selling copies of U.S. drugmaker Merck's diabetes drugs Januvia and Janumet, according to a court document released on Friday. (Source: Reuters: Health)
Source: Reuters: Health - May 15, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Supreme Court bars Glenmark from selling copies of Merck diabetes drugs: Sources
Merck sued Glenmark in 2013 for infringing a patent it has on sitagliptin, the chemical compound in Januvia and Janumet. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 15, 2015 Category: Pharmaceuticals Source Type: news
Cardiovascular Outcomes with Sitagliptin: No Better or Worse Than Conventional Care (FREE)
By Larry Husten
Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM
The diabetes drug sitagliptin (Januvia) is noninferior to usual care in terms of cardiovascular outcomes, according to top-line results of a CV outcomes trial released Monday.The manufacturer announced only one additional detail: "Among secondary endpoints, there was no increase in … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 29, 2015 Category: Primary Care Source Type: news
TECOS Top Line: No Increase in CV Risk with DPP-4 Inhibitor
(MedPage Today) -- Primary and secondary endpoints met for those on sitagliptin. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 28, 2015 Category: Cardiology Source Type: news
